Growing Colorectal Tumor Cells from Patient Samples for Lab Testing
Collects tumor tissue from adults with colorectal cancer to grow cells for lab testing.
Plain-language title generated from the registry record
Registry title: Tailoring Treatment in Colorectal Cancer
Key facts
- Where
- Lørenskog, NorwaySee the site
Where in Norway
- Akershus University HospitalLørenskog, NorwayTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Akershus
- Trial code
- NCT05401318
- Record updated
- 6 August 2024
- Original description
In this study, the investigators will establish a reliable method and logistic pipeline for personalized drug testing ex vivo using fresh tumor samples from colorectal cancer (CRC) patients. With this, the investigators aim to develop a novel predictive biomarker of immunotherapy response, by testing combinations of chemotherapies and chimeric antigen receptor (CAR) T cells. Critically, this affects a large subgroup of patients currently not considered to benefit from such treatment. To support the hypothesis, the project will make use of cutting-edge, cell-based functional diagnostics. Individual patients' cancer cells will be screened against a panel of chemotherapies and targeted therapies including CAR T cells, to assess the optimal combination of therapies to induce immunotherapy efficacy in otherwise unresponsive CRC.Read full original descriptionShow less
Pilot Study for Ex Vivo Tailoring of Treatment in Colorectal Cancer
In this study, the investigators will establish a reliable method and logistic pipeline for personalized drug testing ex vivo using fresh tumor samples from colorectal cancer (CRC) patients. With this, the investigators aim to develop a novel predictive biomarker of immunotherapy response, by testing combinations of chemotherapies and chimeric antigen receptor (CAR) T cells. Critically, this affects a large subgroup of patients currently not considered to benefit from such treatment. To support the hypothesis, the project will make use of cutting-edge, cell-based functional diagnostics. Individual patients' cancer cells will be screened against a panel of chemotherapies and targeted therapies including CAR T cells, to assess the optimal combination of therapies to induce immunotherapy efficacy in otherwise unresponsive CRC.
Inclusion: Histologically confirmed colorectal cancer scheduled for curative surgery and standard clinical follow-up.
Exclusion: Unable/unwilling to sign the informed consent form.